Article
Medicine, General & Internal
R. L. Atmar, K. E. Lyke, M. E. Deming, L. A. Jackson, A. R. Branche, H. M. El Sahly, C. A. Rostad, J. M. Martin, C. Johnston, R. E. Rupp, M. J. Mulligan, R. C. Brady, R. W. Frenck, M. Backer, A. C. Kottkamp, T. M. Babu, K. Rajakumar, S. Edupuganti, D. Dobrzynski, R. N. Coler, C. M. Posavad, J. Archer, S. Crandon, S. U. Nayak, D. Szydlo, J. A. Zemanek, C. P. Dominguez Islas, E. R. Brown, M. S. Suthar, M. J. McElrath, A. B. McDermott, D. C. Montefiori, A. Eaton, K. M. Neuzil, D. S. Stephens, P. C. Roberts, J. H. Beigel
Summary: This study investigated the efficacy of homologous and heterologous booster vaccines in adults who had completed a primary Covid-19 vaccine regimen. The results showed that both types of booster vaccines were safe and immunogenic.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Immunology
Sutima Luangdilok, Passakorn Wanchaijiraboon, Nussara Pakvisal, Thiti Susiriwatananont, Nicha Zungsontiporn, Virote Sriuranpong, Panot Sainamthip, Nungruthai Suntronwong, Preeyaporn Vichaiwattana, Nasamon Wanlapakorn, Yong Poovorawan, Nattaya Teeyapun, Suebpong Tanasanvimon
Summary: This study investigated the immune response of solid cancer patients who previously received a heterologous CoronaVac/ChAdOx1 vaccine to a third mRNA COVID-19 vaccine. Results showed a significant increase in antibody levels after the third dose, with no statistical difference between different vaccine regimens. Endocrine therapy/biologics had a better antibody response compared to chemotherapy. Additionally, there was no significant difference in the immune response after the third dose between cancer patients and healthy individuals who received the same heterologous CoronaVac/ChAdOx1 vaccination.
Article
Immunology
Yunhua Wei, Yan Wang, Jian Liu, Yan Zha, Yuqi Yang, Ni Li, Yalin Zhou, Jinli Zhu, Neil Roberts, Lin Liu, Yaying Li
Summary: A comparative analysis was conducted to investigate the potential risk factors of Adverse Events Following Immunization (AEFI) after receiving different booster vaccines. The study found that doctors and women had a higher risk of adverse reactions, but overall, the rates of AEFI in all three booster groups were acceptable.
Article
Immunology
Leticia Carrijo Masson, Carolina do Prado Servian, Vitor Hugo Jardim, Deborah dos Anjos, Miriam Leandro Dorta, Joao Victor Batalha-Carvalho, Ana Maria Moro, Pedro Roosevelt Torres Romao, Menira Souza, Fabiola Souza Fiaccadori, Simone Goncalves Fonseca
Summary: Immune responses after COVID-19 vaccination were evaluated in different populations. The study found that BNT162b2 vaccine induced higher antibody responses compared to ChAdOx1 nCoV-19 and CoronaVac vaccines. A third dose booster with BNT162b2 increased antibody levels in CoronaVac vaccinees. Individuals with SARS-CoV-2 infection also had higher antibody production.
Article
Immunology
Jing Lian Suah, Boon Hwa Tng, Peter Seah Keng Tok, Masliyana Husin, Thevesh Thevananthan, Kalaiarasu M. Peariasamy, Sheamini Sivasampu
Summary: This study used national administrative data from Malaysia to compare the effectiveness of homologous and heterologous booster vaccinations against SARS-CoV-2 infection. The findings suggest that heterologous boosting with BNT162b2 is preferred for primary vaccination recipients, especially in the Omicron period where the effectiveness of homologous boosters was lower.
EMERGING MICROBES & INFECTIONS
(2022)
Article
Immunology
Yuting Liao, Yingping Chen, Bo Chen, Zhenzhen Liang, Xiaosong Hu, Bo Xing, Juan Yang, Qianhui Zheng, Qianhui Hua, Chuanfu Yan, Huakun Lv
Summary: The study demonstrates that heterologous boosting with ZF2001 is safe and immunogenic. There was no significant correlation between the strength of immune response after the third dose and the original vaccination interval among participants aged 18 and above. Additionally, older adults showed weaker immune responses to the vaccine compared to younger adults.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Multidisciplinary Sciences
Thiago Cerqueira-Silva, Vinicius de Araujo Oliveira, Enny S. Paixao, Juracy Bertoldo Junior, Gerson O. Penna, Guilherme L. Werneck, Neil Pearce, Mauricio L. Barreto, Viviane S. Boaventura, Manoel Barral-Netto
Summary: This study evaluated the vaccine effectiveness of CoronaVac plus BNT162b2 booster during the dominance of the Omicron variant. The results showed that this vaccine combination provided durable and high protection against severe outcomes caused by the Omicron variant, except for individuals aged 80 or older.
NATURE COMMUNICATIONS
(2022)
Article
Immunology
Ayakarn Ruenkham, Suriyon Uitrakul, Peninnah Oberdorfer, Siriporn Okonogi, Wasan Katip
Summary: This study investigated the effectiveness and safety of heterologous CoronaVac-ChAdOx1 and homologous CoronaVac-CoronaVac vaccination regimens. The results showed that both regimens were effective in reducing COVID-19 infection rates and hospitalization rates. Minimal adverse events were reported in both groups, and factors such as age, gender, and body weight were associated with lower adverse events following immunization. The heterologous regimen potentially caused fewer adverse events compared to the homologous regimen.
Article
Immunology
Yun Shan Goh, Siew-Wai Fong, Angeline Rouers, Zi Wei Chang, Matthew Zirui Tay, Jean-Marc Chavatte, Nicole Ziyi Zhuo, Pei Xiang Hor, Chiew Yee Loh, Yuling Huang, Joel Xu En Wong, Yong Jie Tan, Daniel Rui Xiang Lim, Bei Wang, Eve Zi Xian Ngoh, Siti Nazihah Mohd Salleh, Raphael Tze Chuen Lee, Surinder Pada, Louisa Jin Sun, Desmond Luan Seng Ong, Jyoti Somani, Eng Sing Lee, Sebastian Maurer-Stroh, Cheng- Wang, Yee-Sin Leo, Raymond T. P. Lin, Ee Chee Ren, David C. Lye, Barnaby Edward Young, Poh Lian Lim, Lisa F. P. Ng, Laurent Renia
Summary: This study found that individuals who have received mRNA vaccines can choose to receive two doses of CoronaVac as booster shots, but an additional dose may be necessary for full protection, especially against newly emerged immune escape variants such as Omicron.
CLINICAL & TRANSLATIONAL IMMUNOLOGY
(2022)
Article
Virology
Maria Francilene Souza Silva, Ana Carolina Matias Dinelly Pinto, Fatima de Cassia Evangelista de Oliveira, Ludmilla Freire Caetano, Fernanda Montenegro de Carvalho Araujo, Marcela Helena Gambim Fonseca
Summary: This study evaluated antibody levels in individuals who had received the CoronaVac vaccine and then received a booster dose of the BNT162B2 vaccine after 6 months. The study also investigated whether a subsequent SARS-COV-2 infection would enhance the antibody response. The results showed that antibody levels peaked 30 days after the booster dose and gradually declined over time. Infection after vaccination increased antibodies against the nucleocapsid protein. The BNT162B2 vaccine boosted antibody levels against the spike protein, but the levels decreased after 60 days.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Article
Immunology
Oleguer Pares-Badell, Ricardo Zules-Ona, Lluis Armadans, Laia Pinos, Blanca Borras-Bermejo, Susana Otero, Jose angel Rodrigo-Pendas, Marti Vivet-Escale, Yolima Cossio-Gil, Antonia Agusti, Cristina Aguilera, Magda Campins, Xavier Martinez-Gomez
Summary: This study aimed to assess the adverse reactions after the administration of a COVID-19 mRNA-1273 booster in healthcare workers. The study compared the type of mRNA vaccine used as the primary series and the use of homologous versus heterologous boosters. The study found that the reactogenicity of the mRNA-1273 booster was similar to the mRNA-1273 primary doses and higher than the BNT162b2 primary doses. There were no significant differences in local or systemic reactions between receiving a heterologous booster or a homologous booster.
Article
Biochemistry & Molecular Biology
Eddy Perez-Then, Carolina Lucas, Valter Silva Monteiro, Marija Miric, Vivian Brache, Leila Cochon, Chantal B. F. Vogels, Amyn A. Malik, Elena De la Cruz, Aidelis Jorge, Margarita De los Santos, Patricia Leon, Mallery Breban, Kendall Billig, Inci Yildirim, Claire Pearson, Randy Downing, Emily Gagnon, Anthony Muyombwe, Jafar Razeq, Melissa Campbell, Albert Ko, Saad B. Omer, Nathan D. Grubaugh, Sten H. Vermund, Akiko Iwasaki
Summary: The study found that a BNT162b2 mRNA vaccine booster can enhance neutralizing antibodies against the Omicron variant in individuals who received two doses of the CoronaVac vaccine, but antibody titers remain lower compared to the ancestral virus and the Delta variant.
Article
Parasitology
Serkan Atici, Ahmet Soysal, Erdem Gonullu, Gokhan Aydemir, Naci Oner, Servet Alan, Havva Engin, Melek Yildiz, Metin Karabocuoglu
Summary: Heterologous COVID-19 booster vaccination with BNT162b2 effectively boosts neutralizing antibody levels in individuals primed with the CoronaVac vaccine.
REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL
(2023)
Review
Biotechnology & Applied Microbiology
Rituparna Das, Randall N. Hyer, Paul Burton, Jacqueline M. Miller, Barbara J. Kuter
Summary: mRNA-based vaccine platforms have shown great adaptability in fighting against SARS-CoV-2. Heterologous vaccination regimens offer a practical, effective, and safe approach to reduce the global burden of COVID-19.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2023)
Article
Biotechnology & Applied Microbiology
Chenchit Chayachinda, Kanokwaroon Watananirun, Chayawat Phatihattakorn, Sanitra Anuwutnavin, Suvimol Niyomnaitham, Wanatpreeya Phongsamart, Keswadee Lapphra, Orasri Wittawatmongkol, Supattra Rungmaitree, Laddawan Jansarikit, Kobporn Boonnak, Patimaporn Wongprompitak, Sansnee Senawong, Avishek Upadhya, Zheng Quan Toh, Paul V. V. Licciardi, Kulkanya Chokephaibulkit
Summary: This trial evaluated the immunogenicity and reactogenicity of different COVID-19 vaccination schedules in pregnant Thai women. Heterologous schedules of CoronaVac-BNT162b2 or ChAdOx1-BNT162b2 showed similar immunogenicity to BNT162b2-BNT162b2. Neutralizing antibody levels were highest in the CoronaVac-BNT162b2 group. No significant difference in cord blood antibody levels between groups were observed. Local and systemic adverse events were mild-to-moderate and more frequent in the ChAdOx1-BNT162b2 group.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2023)
Article
Immunology
William C. McMahon, Gaurav Kwatra, Alane Izu, Anthonet L. Koen, Johann Greffrath, Lee Fairlie, Faeezah Patel, Christian K. Mukendi, Nkululeko J. Mbele, Rushil Lala, Wendy A. Burgers, Marta C. Nunes, Clare L. Cutland, Sarah C. Gilbert, Teresa Lambe, Andrew J. Pollard, Shabir A. Madhi
Summary: This study aimed to investigate the T-cell responses specific to SARS-CoV-2 in black Africans with and without HIV after receiving the AZD1222 vaccine. The study found that the T-cell responses were comparable between HIV-uninfected individuals and people living with HIV who were on stable antiretroviral therapy. In addition, individuals with prior SARS-CoV-2 infection showed a heightened T-cell response after receiving the AZD1222 vaccine.
Article
Immunology
Merryn Voysey, Amy Flaxman, Jeremy Aboagye, Parvinder K. Aley, Sandra Belij-Rammerstorfer, Sagida Bibi, Mustapha Bittaye, Federica Cappuccini, Sue Charlton, Elizabeth A. Clutterbuck, Sophie Davies, Christina Dold, Nick J. Edwards, Katie J. Ewer, Saul N. Faust, Pedro M. Folegatti, Jamie Fowler, Ciaran Gilbride, Sarah C. Gilbert, Leila Godfrey, Bassam Hallis, Holly E. Humphries, Daniel Jenkin, Simon Kerridge, Yama F. Mujadidi, Emma Plested, Maheshi N. Ramasamy, Hannah Robinson, Helen Sanders, Matthew D. Snape, Rinn Song, Kelly M. Thomas, Marta Ulaszewska, Danielle Woods, Daniel Wright, Andrew J. Pollard, Teresa Lambe
Summary: Two doses of ChAdOx1 nCov-19 vaccine generate persistent spike-specific IgG antibody responses for at least 1 year and potentially up to 2 years. This immune response is associated with a reduced risk of serious disease and hospitalization. Vaccine effectiveness declines over time based on the trajectory of immune responses following the primary dose series.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
(2023)
Article
Infectious Diseases
James Nyagwange, Bernadette Kutima, Kennedy Mwai, Henry K. Karanja, John N. Gitonga, Daisy Mugo, Yiakon Sein, Daniel Wright, Donwilliams O. Omuoyo, Joyce U. Nyiro, James Tuju, D. James Nokes, Ambrose Agweyu, Philip Bejon, Lynette I. Ochola-Oyier, J. Anthony G. Scott, Teresa Lambe, Eunice Nduati, Charles Agoti, George M. Warimwe
Summary: The study found evidence of pre-existing functional humoral responses to SARS-CoV-2 in Kilifi, coastal Kenya, which aligns with findings of pre-existing immunity to COVID-19 in other regions.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Medicine, General & Internal
Khaelqu Zaman, Ananda S. Bandyopadhyay, Masuma Hoque, Christopher Gast, Mohammad Yunus, Khondoker M. Jamil, Bernardo A. Mainou, Jennifer L. Konopka-Anstadt, William S. Hendley, Annelet Vincent, Ralf Clemens, Sue Ann Costa Clemens, Allen G. Ross, John Clemens, Erman Tritama
Summary: A study conducted in Bangladesh found that newborn infants who received the novel type 2 oral poliovirus vaccine (nOPV2) had almost 99% of infants producing protective neutralizing antibodies. The vaccine showed good tolerability and immunogenicity in newborn infants.
Correction
Infectious Diseases
Xinxue Liu, Alasdair P. S. Munro, Shuo Feng, Leila Janani, Parvinder K. Aley, Gavin Babbage, David Baxter, Marcin Bula, Katrina Cathie, Krishna Chatterjee, Wanwisa Dejnirattisai, Kate Dodd, Yvanne Enever, Ehsaan Qureshi, Anna L. Goodman, Christopher A. Green, Linda Harndahl, John Haughney, Alexander Hicks, Agatha A. van der Klaauw, Jonathan Kwok, Vincenzo Libri, Martin J. Llewelyn, Alastair C. McGregor, Angela M. Minassian, Patrick Moore, Mehmood Mughal, Yama Mujadidi, Kyra Holliday, Orod Osanlou, Rostam Osanlou, Daniel R. Owens, Mihaela Pacurar, Adrian Palfreeman, Daniel Pan, Tommy Rampling, Karen Regan, Stephen Saich, Teona Serafimova, Dinesh Saralaya, Gavin R. Screaton, Sunil Sharma, Ray Sheridan, Ann Sturdy, Piyada Supasa, Emma C. Thomson, Shirley Todd, Chris Twelves, Robert C. Read, Sue Charlton, Bassam Hallis, Mary Ramsay, Nick Andrews, Teresa Lambe, Jonathan S. Nguyen-Van-Tam, Victoria Cornelius, Matthew Snape, Saul N. Faust
JOURNAL OF INFECTION
(2023)
Article
Infectious Diseases
Eimear Kelly, Melanie Greenland, Philip C. S. de Whalley, Parvinder K. Aley, Emma L. Plested, Nisha Singh, Stanislava Koleva, Sharon Tonner, Grace C. Macaulay, Robert C. Read, Mary Ramsay, J. Claire Cameron, David P. J. Turner, Paul T. Heath, Jolanta Bernatoniene, Philip Connor, Katrina Cathie, Saul N. Faust, Indraneel Banerjee, Liberty Cantrell, Yama F. Mujadidi, Hanane Trari Belhadef, Elizabeth A. Clutterbuck, Rachel Anslow, Zara Valliji, Tim James, Bassam Hallis, Ashley David Otter, Teresa Lambe, Jonathan S. Nguyen-Van-Tam, Angela M. Minassian, Xinxue Liu, M. D. Snape
Summary: This study investigates the reactogenicity and immunogenicity of heterologous or fractional second dose COVID-19 vaccine regimens in adolescents. The findings suggest that heterologous and fractional dose COVID-19 vaccine schedules in adolescents are safe, well tolerated, and immunogenic.
JOURNAL OF INFECTION
(2023)
Article
Infectious Diseases
Robert H. Shaw, Melanie Greenland, Arabella S. V. Stuart, Parvinder K. Aley, Nick J. Andrews, J. Claire Cameron, Sue Charlton, Elizabeth A. Clutterbuck, Andrea M. Collins, Tom Darton, Tanya Dinesh, Christopher J. A. Duncan, Saul N. Faust, Daniela M. Ferreira, Adam Finn, Anna L. Goodman, Christopher A. Green, Bassam Hallis, Paul T. Heath, Helen Hill, Teresa Lambe, Vincenzo Libri, Patrick J. Lillie, Ella Morey, Yama F. Mujadidi, Ruth Payne, Emma L. Plested, Samuel Provstgaard-Morys, Maheshi N. Ramasamy, Mary Ramsay, Robert C. Read, Hannah Robinson, Gavin R. Screaton, Nisha Singh, David P. J. Turner, Paul J. Turner, Rachel White, Jonathan S. Nguyen-Van-Tam, Xinxue Liu, Matthew D. Snape
Summary: This report aims to understand the persistence of immune response to different COVID-19 vaccine platforms used in homologous and heterologous priming combinations, which will inform future vaccine development.
JOURNAL OF INFECTION
(2023)
Article
Immunology
Paulina Kaplonek, Deniz Cizmeci, Gaurav Kwatra, Alane Izu, Jessica Shih-Lu Lee, Harry L. Bertera, Stephanie Fischinger, Colin Mann, Fatima Amanat, Wenjun Wang, Anthonet L. Koen, Lee Fairlie, Clare L. Cutland, Khatija Ahmed, Keertan Dheda, Shaun L. Barnabas, Qasim Ebrahim Bhorat, Carmen Briner, Florian Krammer, Erica Ollman Saphire, Sarah C. Gilbert, Teresa Lambe, Andrew J. Pollard, Marta Nunes, Manfred Wuhrer, Douglas A. Lauffenburger, Shabir A. Madhi, Galit Alter
Summary: Despite the success of COVID-19 vaccines, breakthrough infections can occur due to SARS-CoV-2 variants. The immune mediators of protection in humans are still unknown. A study on ChAdOx1 nCoV-19 (AZD1222) vaccine recipients in South Africa found different Fc-receptor-binding antibodies among different groups. Individuals who resisted COVID-19 exclusively had Fc gamma R3B-binding antibodies, while those who experienced breakthrough had enhanced IgA and IgG3 with enriched Fc gamma R2B binding. Antibodies unable to bind to Fc gamma R3B led to immune complex clearance and inflammation. The differential antibody binding to Fc gamma R3B was associated with Fc-glycosylation differences in SARS-CoV-2-specific antibodies.
Article
Immunology
Yauba Saidu, Pietro Di Mattei, Sangwe Clovis Nchinjoh, Nnang Nadege Edwige, Bernard Nsah, Nkwain Jude Muteh, Shalom Tchokfe Ndoula, Rakiya Abdullahi, Chen Stein Zamir, Andreas Ateke Njoh, Amani Adidja, Sidy Ndiaye, Owens Wiwa, Emanuele Montomoli, Sue Ann Costa Clemens
Summary: The global pulse survey found that the COVID-19 pandemic disrupted childhood immunization in many countries. However, in Cameroon, national childhood vaccination coverage increased during the pandemic compared to the pre-COVID-19 period. A study was conducted to assess the impact of COVID-19 on childhood vaccination in hotspot regions and found a significant drop in vaccination coverage.
Article
Medicine, Research & Experimental
Shona C. Moore, Barbara Kronsteiner, Stephanie Longet, Sandra Adele, Alexandra S. Deeks, Chang Liu, Wanwisa Dejnirattisai, Laura Silva Reyes, Naomi Meardon, Sian Faustini, Saly Al-Taei, Tom Tipton, Luisa M. Hering, Adrienn Angyal, Rebecca Brown, Alexander R. Nicols, Susan L. Dobson, Piyada Supasa, Aekkachai Tuekprakhon, Andrew Cross, Jessica K. Tyerman, Hailey Hornsby, Irina Grouneva, Megan Plowright, Peijun Zhang, Thomas A. H. Newman, Jeremy M. Nell, Priyanka Abraham, Mohammad Ali, Tom Malone, Isabel Neale, Eloise Phillips, Joseph D. Wilson, Sam M. Murray, Martha Zewdie, Adrian Shields, Emily C. Horner, Lucy H. Booth, Lizzie Stafford, Sagida Bibi, Daniel G. Wootton, Alexander J. Mentzer, Christopher P. Conlon, Katie Jeffery, Philippa C. Matthews, Andrew J. Pollard, Anthony Brown, Sarah L. Rowland-Jones, Juthathip Mongkolsapaya, Rebecca P. Payne, Christina Dold, Teresa Lambe, James E. D. Thaventhiran, Gavin Screaton, Eleanor Barnes, Susan Hopkins, Victoria Hall, Christopher J. A. Ducan, Alex Richter, Miles Carroll, Thushan I. de Silva, Paul Klenerman, Susann Dunachie, Lance Turtle, PITCH Consortium
Summary: In this study, the researchers observed the immune response changes in 684 UK healthcare workers after receiving two doses of BNT162b2 or AZD1222 vaccines during a follow-up period of 6-9 months. The study found that the antibody and memory B cell responses were relatively stable, while the levels of binding and neutralizing antibodies declined. The study also found that individuals with prior infection had stronger and broader T cell responses to the vaccine, especially after receiving the third dose.
Article
Biotechnology & Applied Microbiology
Sue Ann Costa Clemens, Natalie Marchevsky, Sarah Kelly, Sally Felle, Ahmed Eldawi, Rupetha Rajasingam, Rawan Mahmud, Teresa Lambe, Merryn Voysey, Isabela Gonzalez, Eveline Pipolo Milan, Maria Cleonice Justino, Sagida Bibi, Parvinder Aley, Ralf Clemens, Andrew J. J. Pollard
Summary: In this phase 4 study of Brazilian adults who were previously vaccinated with two doses of CoronaVac, boosting with fractional doses of heterologous COVID-19 vaccines was assessed. The study found that the seroresponse rates at Day 28 did not meet the primary objective of 80%, despite robust immune responses in all three groups. Heterologous boosting with ChAdOx1-S or BNT162b2 was safe and immunogenic in individuals primed with CoronaVac, but limited by high baseline immunity.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2023)
Article
Immunology
Erika Zoe Lopatynsky-Reyes, Enrique Chacon-Cruz, Michael Greenberg, Ralf Clemens, Sue Ann Costa Clemens
Summary: The knowledge and beliefs of Mexican OBGYNs and FPs regarding influenza during pregnancy and the importance of influenza vaccination are not optimal.
Article
Public, Environmental & Occupational Health
Sue Ann Costa Clemens, Gustavo Mendes Lima Santos, Isabela Gonzalez, Ralf Clemens
Summary: Poliovirus infection can cause paralysis in 1 out of every 200 infected individuals. While the use of inactivated poliovirus vaccines and live attenuated oral poliovirus vaccines has largely eradicated the wildtype poliovirus, outbreaks of circulating vaccine-derived poliovirus still occur due to the reversion of the vaccine strains to virulence.
REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH
(2023)
Article
Public, Environmental & Occupational Health
Yauba Saidu, Valirie N. Agbor, Pietro Di Mattei, Sangwe C. Nchinjoh, Nnang N. Edwidge, Andreas A. Njoh, Nkwain J. Muteh, Marta Prescott, Owens Wiwa, Demba Diack, Junie Flegere, Emanuele Montomoli, Sue A. Costa Clemens, Ralf Clemens
Summary: Millions of children, particularly in developing countries, have not received the DTP vaccine, making them zero-dose children (ZDC). Due to unreliable denominators used to calculate vaccination coverage, identifying and prioritising communities for catch-up vaccination is challenging. Incorporating other indicators of access and utilisation of vaccination services can help identify and rank missed communities based on the likelihood of finding ZDC.
JOURNAL OF GLOBAL HEALTH
(2023)
Article
Health Policy & Services
Yauba Saidu, Jessica Gu, Budzi Michael Ngenge, Sangwe Clovis Nchinjoh, Amani Adidja, Nadege Edwidge Nnang, Nkwain Jude Muteh, Vouking Marius Zambou, Clarence Mvalo Mbanga, Valirie Ndip Agbor, Diaby Ousmane, Andreas Ateke Njoh, Junie Flegere, Demba Diack, Owens Wiwa, Emanuele Montomoli, Sue Ann Costa Clemens, Ralf Clemens
Summary: This study in Cameroon revealed deficits in immunization knowledge among vaccination staff, as well as concerning practices. The findings emphasize the urgent need to invest in comprehensive capacity building of vaccination staff in order to improve vaccination coverage and equity.
HUMAN RESOURCES FOR HEALTH
(2023)